Work

Abstract CT-08: A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors

Year: 2012

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2012-ct-08

Authors: Dejan Juric, Rodrigo Dienstmann, Wells Messersmith, Andres Cervantes, George Blumenschein, Jose Baselga, Josep Tabernero, Antonio Jimeno, Antonio Calles, Desamparados Roda, Yan Xin, Amy V. Kapp, G. Scott Chandler, Andrea Pirzkall, Manuel Hidalgo

Institutions: Massachusetts General Hospital, Vall d'Hebron Institute of Oncology, University of Colorado Cancer Center, Universitat de València, INCLIVA Health Research Institute, The University of Texas MD Anderson Cancer Center, Spanish National Cancer Research Centre

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1992478608

Cites:

Cited by: 4

Related to: 10